Zenotech Laboratories Ltd Stock Price Today (NSE: ZENOTECH)
Fundamental Score
Zenotech Laboratories Ltd Share Price — Live NSE/BSE Price, Fundamentals & Analysis
Zenotech Laboratories Ltd share price today is ₹44.35, up +0.20% on NSE/BSE as of 16 September 2026. Zenotech Laboratories Ltd (ZENOTECH) is a Small-cap company in the Pharmaceuticals sector with a market capitalisation of ₹270.67 (Cr). The 52-week high for ZENOTECH share price is ₹56.99 and the 52-week low is ₹33.55. The company has a Return on Equity (ROE) of -1.12% and a debt-to-equity ratio of N/A.
Zenotech Laboratories Ltd Share Price Chart — NSE/BSE Historical Performance
Zenotech Laboratories Ltd share price chart: -2.18% return over the past month. 52-week high ₹56.99, 52-week low ₹33.55.
Zenotech Laboratories Ltd — Last 10 Trading Days
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| ₹44.58 | ₹44.85 | ₹44.07 | ₹44.35 | 3.98K (Cr) | |
| ₹44.58 | ₹45.43 | ₹43.76 | ₹44.26 | 6.50K (Cr) | |
| ₹45.06 | ₹45.86 | ₹43.45 | ₹44.98 | 2.67K (Cr) | |
| ₹45.39 | ₹46.19 | ₹44.28 | ₹44.67 | 10.27K (Cr) | |
| ₹46.68 | ₹47.00 | ₹44.52 | ₹45.39 | 14.02K (Cr) | |
| ₹46.50 | ₹48.00 | ₹45.52 | ₹46.26 | 14.48K (Cr) | |
| ₹45.99 | ₹46.90 | ₹45.18 | ₹46.09 | 6.48K (Cr) | |
| ₹46.44 | ₹46.44 | ₹45.11 | ₹45.60 | 8.23K (Cr) | |
| ₹45.99 | ₹47.00 | ₹45.50 | ₹45.59 | 10.48K (Cr) | |
| ₹45.58 | ₹46.90 | ₹44.65 | ₹45.87 | 15.04K (Cr) |
Zenotech Laboratories Ltd — Last 12 Months Price History
| Month | Open | High | Low | Close | Change |
|---|---|---|---|---|---|
| ₹45.37 | ₹48.00 | ₹43.45 | ₹44.35 | -2.25% | |
| ₹44.20 | ₹45.50 | ₹43.11 | ₹44.63 | +0.97% | |
| ₹44.00 | ₹48.00 | ₹42.90 | ₹44.78 | +1.77% | |
| ₹35.90 | ₹49.94 | ₹35.90 | ₹43.61 | +21.48% | |
| ₹44.61 | ₹46.80 | ₹33.55 | ₹34.29 | -23.13% | |
| ₹44.99 | ₹47.89 | ₹43.05 | ₹45.12 | +0.29% | |
| ₹46.99 | ₹50.93 | ₹43.01 | ₹44.76 | -4.75% | |
| ₹48.76 | ₹49.00 | ₹43.85 | ₹46.19 | -5.27% | |
| ₹49.90 | ₹53.50 | ₹47.50 | ₹48.65 | -2.51% | |
| ₹52.50 | ₹54.14 | ₹48.00 | ₹53.49 | +1.89% | |
| ₹56.99 | ₹56.99 | ₹48.55 | ₹52.50 | -7.88% |
Returns & Performance
Return on Equity (ROE)
Profit generated per ₹1 of shareholder equity
Return on Capital (ROCE)
Returns generated on total capital deployed
Oper. Profit Margin (5Y Avg)
Average operating profit margin over 5 years
Dividend Yield
Annual dividend as % of current share price
Zenotech Laboratories Ltd Valuation Check
Price to Earnings (P/E)
Share price ÷ earnings per share. Lower = cheaper
Industry Avg P/E
Average P/E of all peers in this sector
Market Capitalisation
Total market value of all outstanding shares
Growth Engine
Profit Growth (Quarterly YoY)
Net profit growth vs same quarter last year
Revenue Growth (Quarterly YoY)
Revenue growth vs same quarter last year
Revenue Growth (5-Year CAGR)
Compounded annual revenue growth over 5 years
EPS Growth (5-Year CAGR)
Earnings per share growth over 5 years
Net Profit Growth (5-Year CAGR)
Compounded annual net profit growth over 5 years
Balance Sheet Health
Debt to Equity Ratio
Total debt ÷ equity. Below 0.5 = financially healthy
Interest Coverage Ratio
EBIT ÷ interest expense. Above 2.5 = can pay interest comfortably
Free Cash Flow (5-Year Total)
Cash left after capex over 5 years. Positive = self-funded growth
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Zenotech Laboratories Ltd Fundamental Analysis & Valuation Benchmarking
Educational evaluation of ZENOTECH across key market metrics for learning purposes.
Positive Indicators
6 factors identified
Strong Operating Margins (38.17%)
Observation: Healthy 5-year operating margins indicate pricing power and cost control.
Analysis: OPM >15% suggests operational efficiency and competitive advantages.
Consistent Growth Track Record (14.20% CAGR)
Observation: Strong 5-year sales compound annual growth rate.
Analysis: Consistent sales CAGR >12% demonstrates sustainable growth model.
Healthy Liquidity Position (Current Ratio: 2.86)
Observation: Strong short-term liquidity to meet obligations.
Analysis: Current ratio >1.5 indicates good working capital management.
Strong Cash Generation (₹45.30 Cr over 5Y)
Observation: Healthy free cash flow generation supports growth and returns.
Analysis: Strong FCF provides flexibility for dividends, debt reduction, and growth investments.
Balanced Promoter Holding (68.84%)
Observation: Optimal balance between promoter control and public float.
Analysis: Promoter holding in 50-75% range provides management alignment.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral.
Analysis: Absence of share pledging eliminates potential forced-selling pressure.
Risk Factors
7 factors identified
Below-Average Return on Equity (-1.12%)
Observation: Returns on equity are below industry benchmarks.
Analysis: ROE <10% may indicate inefficient capital utilization. Consider monitoring for operational improvements and management effectiveness.
Suboptimal ROCE (-1.92%)
Observation: Returns on capital employed are below expectations.
Analysis: ROCE <10% suggests potential inefficiencies in capital allocation.
Profit Decline Concern (-146.48%)
Observation: Significant year-over-year profit contraction observed.
Analysis: Declining profitability requires investigation into underlying causes.
Weak Earnings Growth (1.59% CAGR)
Observation: Below-average 5-year EPS growth performance.
Analysis: Low EPS growth may not keep pace with inflation.
Stagnant Profit Growth (1.59% CAGR)
Observation: Limited 5-year profit growth trajectory.
Analysis: Low profit growth may indicate scalability challenges or market maturity.
Limited Institutional Interest (FII+DII: 0.01%)
Observation: Low institutional participation may affect liquidity.
Analysis: Limited institutional interest may indicate size constraints or visibility issues.
No Dividend Distribution
Observation: Company does not currently pay dividends to shareholders.
Analysis: Zero dividend yield may indicate growth reinvestment focus or cash flow constraints.
Zenotech Laboratories Ltd vs Pharmaceuticals Peers
Peer Comparison - Pharmaceuticals
Compare Zenotech Laboratories Ltd with 10 other companies in the same sector
| Company Info | Fundamental | Valuation | Profitability | Financial Health | Growth | Dividend | ||||
|---|---|---|---|---|---|---|---|---|---|---|
Company Company name | Score Bull Run comprehensive fundamental score based on 20+ metrics | Price Current trading price of the stock | Market Cap Total value of all shares in the market | P/E Price per share divided by earnings per share | ROE Net income divided by shareholder equity | ROCE Earnings before interest and tax divided by capital employed | Debt/Eq Total debt divided by total equity | Profit 5Y Average annual profit growth over 5 years | Sales 5Y Average annual sales growth over 5 years | Dividend Annual dividend per share divided by price per share |
Zenotech Laboratories LtdZenotech Labora...Selected✓ ZENOTECH • 532039 | 25.9/100 | ₹44.35₹44 | ₹270.67₹270.67 | — — | -1.12%Poor -1.12% Poor | -1.92%Poor -1.92% Poor | — — | 1.59%Average 1.59% Average | 14.20%Good 14.20% Good | 0.00% |
Sun Pharmaceutical Industries LimitedSun Pharmaceuti... SUNPHARMA • 524715 | 66.4/100 | ₹1864.90₹1865 | ₹447445.46₹447445.46 | 37.00Average 37.0 Average | 14.74%Average 14.74% Average | 19.31%Good 19.31% Good | 0.05Excellent 0.0 Excellent | 31.64%Excellent 31.64% Excellent | 11.78%Good 11.78% Good | 0.82% |
Divi's Laboratories LimitedDivi's Laborato... DIVISLAB • 532488 | 56.3/100 | ₹9488.00₹9488 | ₹251432.00₹251432.00 | 86.09Average 86.1 Average | 16.19%Good 16.19% Good | 20.38%Excellent 20.38% Excellent | 0.00Excellent 0.0 Excellent | 5.29%Good 5.29% Good | 8.67%Good 8.67% Good | 0.41% |
Torrent Pharmaceuticals LimitedTorrent Pharmac... TORNTPHARM • 500420 | 51.4/100 | ₹4930.00₹4930 | ₹166860.78₹166860.78 | 78.75Average 78.8 Average | 27.07%Excellent 27.07% Excellent | 14.09%Average 14.09% Average | 1.76Average 1.8 Average | 11.56%Good 11.56% Good | 11.80%Good 11.80% Good | 0.76% |
Zydus Lifesciences LimitedZydus Lifescien... ZYDUSLIFE • 532321 | 74.1/100 | ₹1127.40₹1127 | ₹112514.52₹112514.52 | 25.13Average 25.1 Average | 19.74%Good 19.74% Good | 21.77%Excellent 21.77% Excellent | 0.43Excellent 0.4 Excellent | 18.76%Excellent 18.76% Excellent | 12.45%Good 12.45% Good | 0.09% |
Cipla LimitedCipla Limited... CIPLA • 500087 | 40.2/100 | ₹1363.10₹1363 | ₹110118.03₹110118.03 | 32.66Average 32.7 Average | 11.82%Average 11.82% Average | 15.67%Good 15.67% Good | 0.01Excellent 0.0 Excellent | 10.03%Good 10.03% Good | 8.01%Good 8.01% Good | 0.90% |
Laurus Labs LimitedLaurus Labs Lim... LAURUSLABS • 540222 | 34.1/100 | ₹1937.00₹1937 | ₹104646.43₹104646.43 | 95.61Average 95.6 Average | 18.19%Good 18.19% Good | 21.35%Excellent 21.35% Excellent | 0.45Excellent 0.5 Excellent | -1.89%Poor -1.89% Poor | 7.19%Good 7.19% Good | 0.13% |
Aurobindo Pharma LimitedAurobindo Pharm... AUROPHARMA • 524804 | 24.6/100 | ₹1698.90₹1699 | ₹97754.71₹97754.71 | 26.55Average 26.5 Average | 9.94%Poor 9.94% Poor | 14.54%Average 14.54% Average | 0.20Excellent 0.2 Excellent | -8.07%Poor -8.07% Poor | 6.32%Good 6.32% Good | 0.26% |
Lupin LimitedLupin Limited... LUPIN • 500257 | 83.4/100 | ₹2100.00₹2100 | ₹96022.50₹96022.50 | 17.35Average 17.4 Average | 26.90%Excellent 26.90% Excellent | 31.80%Excellent 31.80% Excellent | 0.26Excellent 0.3 Excellent | 34.39%Excellent 34.39% Excellent | 13.02%Good 13.02% Good | 0.72% |
Dr. Reddy's Laboratories LimitedDr. Reddy's Lab... DRREDDY • 500124 | 41/100 | ₹1145.00₹1145 | ₹95607.50₹95607.50 | 29.59Average 29.6 Average | 11.75%Average 11.75% Average | 14.80%Average 14.80% Average | 0.17Excellent 0.2 Excellent | 16.54%Excellent 16.54% Excellent | 12.09%Good 12.09% Good | 0.65% |
Mankind Pharma LimitedMankind Pharma ... MANKIND • 543904 | 61.5/100 | ₹2265.00₹2265 | ₹93544.50₹93544.50 | 45.77Average 45.8 Average | 12.49%Average 12.49% Average | 13.56%Average 13.56% Average | 0.39Excellent 0.4 Excellent | 10.52%Good 10.52% Good | 18.10%Excellent 18.10% Excellent | 0.04% |
Top Pharmaceuticals Stocks
View all →By Bull Run Score
By Return on Equity
By Market Cap
- Sun Pharmaceutical Industries Limited share price447445.46 Cr
- Divi's Laboratories Limited share price251432.00 Cr
- Torrent Pharmaceuticals Limited share price166860.78 Cr
- Zydus Lifesciences Limited share price112514.52 Cr
- Cipla Limited share price110118.03 Cr
Zenotech Laboratories Ltd PE Ratio History
Historical price-to-earnings ratio for ZENOTECH — last 5 years
| Year | EPS (₹) | Price (₹) | P/E Ratio |
|---|---|---|---|
| FY 2025 | ₹0.92 | ₹46.19 | 50.2x |
| FY 2024 | ₹1.36 | ₹71.99 | 52.9x |
P/E = year-end price ÷ diluted EPS from annual filings. Source: NSE/BSE via Bull Run.
Zenotech Laboratories Ltd Quarterly Performance
Latest quarterly metrics for ZENOTECH — revenue growth and profit growth vs same quarter last year
Revenue Growth (YoY)
11.12%
Latest quarter vs same quarter previous year
Net Profit Growth (YoY)
-146.48%
Latest quarter net profit vs same quarter previous year
5-Year Revenue CAGR
14.20%
Compounded annual revenue growth over 5 years
5-Year Profit CAGR
1.59%
Compounded annual net profit growth over 5 years
Zenotech Laboratories Ltd Technical Indicators
SMA 50, SMA 200, RSI and volume signals for ZENOTECH — calculated from daily price history
Momentum is balanced — neither overbought nor oversold.
Technical indicators are for educational purposes only. Not investment advice.
Zenotech Laboratories Ltd Financial Statements
Annual income statement, balance sheet and cash flow for Zenotech Laboratories Ltd (ZENOTECH) — sourced from NSE/BSE filings.
Financial Results & Statements
Latest quarterly, annual and period-wise financial data for Zenotech Laboratories Ltd
About ZENOTECH (Zenotech Laboratories Ltd)
Zenotech Laboratories Ltd is a pioneering pharmaceutical company deeply rooted in the vibrant Indian market. With a sharp focus on specialty generic injectables, ZENOTECH dedicates... its resources to the critical fields of oncology and anesthesiology, striving to deliver accessible and affordable solutions for patients in need. The company operates with a commitment to quality and innovation, constantly seeking to refine existing formulations and explore new avenues for therapeutic intervention. More than just a manufacturer, ZENOTECH is a partner in healthcare, understanding the evolving needs of clinicians and patients alike. Beyond its core product portfolio, ZENOTECH extends its expertise through comprehensive contract manufacturing services. Specializing in parenteral depot formulations, ophthalmic solutions, oncology treatments (both oral and injectable), and general injectables, the company offers tailored solutions to meet the unique requirements of its partners. ZENOTECH's state-of-the-art facilities and experienced team ensure the highest standards of quality and compliance throughout the manufacturing process. This dedication to excellence has established ZENOTECH as a trusted and reliable partner for pharmaceutical companies seeking to expand their reach and capabilities. ZENOTECH further leverages its assets through strategic leasing of its advanced biotech facility and equipment. This offering provides access to cutting-edge infrastructure for companies seeking to conduct research, development, or manufacturing activities. Complementing its core pharmaceutical offerings, ZENOTECH also provides essential supportive care products such as granulocyte-colony stimulating factor and granulocyte-macrophage colony-stimulating factor. Through its multifaceted approach, ZENOTECH Laboratories Ltd plays a vital role in advancing healthcare and fostering innovation within the pharmaceutical landscape.
Company Details
Key Leadership
ZENOTECH Share Price: Frequently Asked Questions
What is the current share price of Zenotech Laboratories Ltd?
Zenotech Laboratories Ltd (ZENOTECH) trades at ₹44.35 on NSE and BSE. Market cap ₹270.67 (Cr). Educational data only.
What is the P/E ratio of Zenotech Laboratories Ltd?
Zenotech Laboratories Ltd has a P/E of N/Ax vs industry average 34.89x.
What is the Bull Run score for Zenotech Laboratories Ltd?
Zenotech Laboratories Ltd has a Bull Run score of 25.9/100 based on 25+ financial parameters.
Does Zenotech Laboratories Ltd pay dividends?
Zenotech Laboratories Ltd has a dividend yield of 0.00%. Past dividends don't guarantee future payments.
What is the ROE of Zenotech Laboratories Ltd?
Zenotech Laboratories Ltd has ROE of -1.12%. Higher ROE indicates better use of shareholder equity.
What is the debt-to-equity ratio of Zenotech Laboratories Ltd?
Zenotech Laboratories Ltd has debt-to-equity of N/A.
Is Zenotech Laboratories Ltd a good investment?
Bull Run gives Zenotech Laboratories Ltd a score of 25.9/100. This is not investment advice — consult a SEBI-registered advisor.